Will Robots Take Their Place in Orthopedics?
Robots are becoming more central to the orthopedic field, but widespread adoption still faces considerable hurdles.
Editor's note: At the time of publication (Aug. 28, 2016), a family member of the analyst owned shares in Stryker (SYK) in an account managed by a third party. Morningstar has confirmed that her ownership of Stryker did not influence any ratings or analysis.
While using robots for surgery has been on the periphery for more than two decades, they have become more central to the orthopedic field over the past several years, especially with the purchase of Mako by Stryker (SYK) and the acquisition of Blue Belt by Smith & Nephew (SNN). In the hands of these larger competitors, we expect robotic surgery to expand its application in orthopedics over the next five years. However, ambiguity around the clinical utility of robots and caution among surgeons could keep the adoption curve gradual over the next five to 10 years. There are definitely challenges to the adoption of this technology.
Debbie Wang does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.